DiscoverPeerVoice Oncology & Haematology VideoJonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC
Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC

Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC

Update: 2024-06-03
Share

Description

Visit https://www.peervoice.com/QHY860 to view the entire programme with slides. After completing “Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC”, participants will be able to: A key challenge is that physicians cannot simply order a “MET test”; different tests must be used to detect the different alterations;; Exon 14 skipping mutations, amplification, and fusion can be detected via DNA or RNA-based next-generation sequencing (NGS);; Amplification and fusion may also be detected by fluorescence in situ hybridization (FISH);; and Overexpression is detected via immunohistochemistry (IHC)..
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC

Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC

PeerVoice